A citation-based method for searching scientific literature

Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.
Norio Akuta, Yusuke Kawamura, Chizuru Watanabe, Akihiro Nishimura, Minoru Okubo, Yasumichi Mori, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi,[...]. Hepatol Res 2019
56
33

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
325
33


Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes.
Jaakko Helve, Reijo Sund, Martti Arffman, Valma Harjutsalo, Per-Henrik Groop, Carola Grönhagen-Riska, Patrik Finne. Diabetes Care 2018
43
33

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
331
33

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
M Loredana Marcovecchio, Scott T Chiesa, Simon Bond, Denis Daneman, Sarah Dawson, Kim C Donaghue, Timothy W Jones, Farid H Mahmud, Sally M Marshall, H Andrew W Neil,[...]. N Engl J Med 2017
62
33

Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption.
Avry Chagnac, Michal Herman, Boris Zingerman, Arie Erman, Benaya Rozen-Zvi, Judith Hirsh, Uzi Gafter. Nephrol Dial Transplant 2008
116
33

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink,[...]. N Engl J Med 2013
619
33

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
21
33


Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.
Norio Akuta, Chizuru Watanabe, Yusuke Kawamura, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi,[...]. Hepatol Commun 2017
70
33

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
792
33


Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria.
Akinobu Nakamura, Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Yoshio Kurihara. Diabetol Metab Syndr 2020
7
33


Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler, Rury R Holman. Diabetes 2006
586
33

Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis.
J-M Petit, L Pedro, B Guiu, L Duvillard, B Bouillet, V Jooste, M Habchi, E Crevisy, C Fourmont, P Buffier,[...]. Diabet Med 2015
25
33

Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.
Meredith C Foster, Shih-Jen Hwang, Martin G Larson, Judith H Lichtman, Nisha I Parikh, Ramachandran S Vasan, Daniel Levy, Caroline S Fox. Am J Kidney Dis 2008
238
33

Sodium-glucose cotransporters: Functional properties and pharmaceutical potential.
Ryuhei Sano, Yuichi Shinozaki, Takeshi Ohta. J Diabetes Investig 2020
23
33

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
31
33

The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
Aila J Ahola, Niina Sandholm, Carol Forsblom, Valma Harjutsalo, Emma Dahlström, Per-Henrik Groop. Kidney Int 2017
30
33



Obesity and risk for chronic renal failure.
Elisabeth Ejerblad, C Michael Fored, Per Lindblad, Jon Fryzek, Joseph K McLaughlin, Olof Nyrén. J Am Soc Nephrol 2006
412
33

Diabetic Kidney Disease: Is There a Role for Glycemic Variability?
Savitha Subramanian, Irl B Hirsch. Curr Diab Rep 2018
7
33

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
Sarayut Lahnwong, Siriporn C Chattipakorn, Nipon Chattipakorn. Cardiovasc Diabetol 2018
79
33

Diabetes and CKD in the United States Population, 2009-2014.
Leila R Zelnick, Noel S Weiss, Bryan R Kestenbaum, Cassianne Robinson-Cohen, Patrick J Heagerty, Katherine Tuttle, Yoshio N Hall, Irl B Hirsch, Ian H de Boer. Clin J Am Soc Nephrol 2017
77
33


SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
Soravis Osataphan, Chiara Macchi, Garima Singhal, Jeremy Chimene-Weiss, Vicencia Sales, Chisayo Kozuka, Jonathan M Dreyfuss, Hui Pan, Yanin Tangcharoenpaisan, Jordan Morningstar,[...]. JCI Insight 2019
76
33

Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.
Eugene J Barrett, Zhenqi Liu, Mogher Khamaisi, George L King, Ronald Klein, Barbara E K Klein, Timothy M Hughes, Suzanne Craft, Barry I Freedman, Donald W Bowden,[...]. J Clin Endocrinol Metab 2017
185
33


Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
107
33

Uric acid as a mediator of diabetic nephropathy.
Diana I Jalal, David M Maahs, Peter Hovind, Takahiko Nakagawa. Semin Nephrol 2011
54
33

Uric acid as a biomarker and a therapeutic target in diabetes.
Yuliya Lytvyn, Bruce A Perkins, David Z I Cherney. Can J Diabetes 2015
66
33

Diagnosis of diabetic kidney disease: state of the art and future perspective.
Frederik Persson, Peter Rossing. Kidney Int Suppl (2011) 2018
109
33

Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study.
Anna Möllsten, Maria Svensson, Ingeborg Waernbaum, Yonas Berhan, Staffan Schön, Lennarth Nyström, Hans J Arnqvist, Gisela Dahlquist. Diabetes 2010
64
33


Chronic kidney disease: global dimension and perspectives.
Vivekanand Jha, Guillermo Garcia-Garcia, Kunitoshi Iseki, Zuo Li, Saraladevi Naicker, Brett Plattner, Rajiv Saran, Angela Yee-Moon Wang, Chih-Wei Yang. Lancet 2013
33

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Am J Nephrol 2019
66
33

Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Sunil V Badve, Elaine M Pascoe, Anushree Tiku, Neil Boudville, Fiona G Brown, Alan Cass, Philip Clarke, Nicola Dalbeth, Richard O Day, Janak R de Zoysa,[...]. N Engl J Med 2020
138
33


Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
111
33

Hypoxia in diabetic kidneys.
Yumi Takiyama, Masakazu Haneda. Biomed Res Int 2014
57
33

Renal physiology of glucose handling and therapeutic implications.
David Z Cherney, Mehmet Kanbay, Julie A Lovshin. Nephrol Dial Transplant 2020
31
33

Progression of Diabetic Kidney Disease in the Absence of Albuminuria.
Richard J MacIsaac, Elif I Ekinci. Diabetes Care 2019
10
33

Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States.
Stephanie N DuBose, Julia M Hermann, William V Tamborlane, Roy W Beck, Axel Dost, Linda A DiMeglio, Karl Otfried Schwab, Reinhard W Holl, Sabine E Hofer, David M Maahs. J Pediatr 2015
107
33



Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
139
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.